Histamine Completed Phase 3 Trials for Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00003991Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia